
Oriza Holdings
Description
Oriza Holdings is a prominent state-owned investment platform based in Suzhou, China, established in 2007. It operates as a comprehensive financial holding group, encompassing a wide array of services including equity investment, debt financing, and professional fund management. Its mandate extends to fostering economic development and industrial upgrading, primarily within the Yangtze River Delta region and across China, by deploying capital into strategic emerging industries.
The firm boasts a significant scale and influence within the Chinese investment landscape. Oriza Holdings manages assets exceeding 300 billion RMB, equivalent to approximately $41 billion USD, making it one of the largest state-backed investment entities in the country. This vast capital base enables it to establish and manage over 100 specialized funds, covering various stages from early-stage venture capital to mature private equity and industry-specific funds.
Oriza Holdings' investment strategy is comprehensive, targeting companies across their entire lifecycle, from nascent startups to established enterprises seeking growth capital or pre-IPO funding. The firm primarily focuses on high-growth sectors critical to China's economic transformation, including TMT (Technology, Media, and Telecommunications), biomedicine, new energy, and advanced manufacturing. With a robust portfolio of over 1,000 companies, Oriza Holdings plays a crucial role in nurturing innovation and supporting the industrial upgrade of its target regions.
Through its diversified fund structure and strategic focus, Oriza Holdings has cemented its position as a key driver of technological and industrial advancement in China. Its capacity to deploy significant capital across various stages and sectors underscores its strategic importance in shaping the nation's future economic landscape.
Investor Profile
Oriza Holdings has backed more than 42 startups, with 19 new investments in the last 12 months alone. The firm has led 5 rounds, about 12% of its total and boasts 16 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series A, Series B, Series C rounds (top funding stages).
- Majority of deals are located in China, United States.
- Strong thematic focus on Manufacturing, Biotechnology, Health Care.
- Led 4 rounds in the past year.
- Typical check size: $2M – $100M.
Stage Focus
- Series A (31%)
- Series B (24%)
- Series C (21%)
- Seed (10%)
- Series D (5%)
- Series Unknown (5%)
- Series E (2%)
- Private Equity (2%)
Country Focus
- China (86%)
- United States (14%)
Industry Focus
- Manufacturing
- Biotechnology
- Health Care
- Biopharma
- Medical
- Semiconductor
- Electronics
- Industrial
- Pharmaceutical
- Robotics
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.